FORSCHUNGSGESELLSCHAFT FUR ARBEITSPHYSIOLOGIE UND ARBEITSSCHUTZ EV

Their core work

IfADo (Leibniz Research Centre for Working Environment and Human Factors) is a German research institute that studies how work affects human health and performance — from the molecular level up to cognitive and behavioral processes. Their core expertise spans neuroscience, toxicology, and ergonomics, applied specifically to occupational health and safety challenges. They develop computational models for toxicity assessment, investigate brain function and consciousness, and design human-centered approaches to human-robot collaboration in industrial settings. Based in Dortmund, they bridge fundamental biomedical research with practical workplace applications.

What they specialise in

How they've shifted over time

In their early H2020 period (2016–2018), IfADo focused on fundamental biomedical research: computational toxicology with adverse outcome pathways (EU-ToxRisk), consciousness neuroscience (LUMINOUS), and bone metabolism (DeBoRA). From 2019 onward, their work shifted markedly toward applied digital technologies — human-robot collaboration, digital twins, prescriptive AI, and non-invasive brain stimulation using computational models. The through-line is computational modelling of human systems, but the application domain has moved from lab-based toxicology and basic neuroscience toward workplace technology and clinical neurostimulation.

IfADo is moving from traditional biomedical research toward applied AI and digital twin technologies for workplace and clinical applications — a strong signal for partners seeking human factors expertise in Industry 4.0 or digital health.

How they like to work

IfADo operates overwhelmingly as a consortium partner (6 of 7 projects), contributing specialized expertise in human factors, toxicology, or neuroscience to larger teams. With 91 unique partners across 17 countries, they maintain a broad European network rather than relying on a small circle of repeat collaborators. Their single coordination (DeBoRA, a small MSCA fellowship) suggests they prefer the specialist contributor role in large Research and Innovation Actions rather than leading consortia.

IfADo has collaborated with 91 distinct partners across 17 countries, indicating a wide and well-connected European network. Their partnerships span health, digital technology, and research excellence sectors, with no strong geographic bias beyond the expected Western European concentration.

What sets them apart

IfADo occupies a rare intersection: they combine deep expertise in human physiology and neuroscience with growing capabilities in digital technologies like AI, digital twins, and computational modelling. This makes them uniquely qualified for projects where understanding the human body and brain must be integrated with digital systems — whether that means modelling drug toxicity computationally or designing robot co-workers that respect human ergonomic limits. Few organizations can credibly contribute to both a consciousness neuroscience project and a collaborative robotics project.

Highlights from their portfolio

• EU-ToxRisk
  Their largest project by funding (EUR 930K), part of a major European flagship program to replace animal testing with mechanism-based toxicity assessment.
• Neurotwin
  Second-largest funding (EUR 928K) and represents their newest research direction — applying digital twin technology to brain stimulation for Alzheimer's disease.
• FELICE
  Demonstrates their pivot into Industry 4.0, combining their human factors expertise with collaborative robotics, computer vision, and prescriptive AI in manufacturing.